Atirmociclib

N/A

Report date: 2026/03/04 20:01:44
NME

Base Information

Drug NameAtirmociclib
Drug Alias NamePF-07220060PF 07220060
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 4 inhibitors
TargetsCyclin-dependent kinase 4
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursProstatic Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[34] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer IncPfizer Investment Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursProstatic NeoplasmsBreast Neoplasms +[5] 
Inactive IndicationsMetastatic breast cancer

Other Information

ATC CodeN/A
Related LinksN/A